Nautilus Biotechnology (NAUT) EBT (2020 - 2026)
Nautilus Biotechnology's (NAUT) quarterly EBT came in at -$14.5 million in Q2 2026, up 3.84% year-over-year from -$13.9 million in Q2 2025, and up 3.84% quarter-over-quarter from -$15.0 million in Q2 2025.
Powered by 
Analysis
Nautilus Biotechnology (NAUT) EBT (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has disclosed EBT across 4 years of filings, most recently posting -$14.5 million for Q2 2026.
- In Q2 2026, EBT rose 3.84% year-over-year to -$14.5 million; the TTM figure through Jun 2026 stood at -$31.8 million (down 81.19% YoY), while the FY2020 annual figure was -$576035.0, changed N/A from the prior year.
- EBT came in at -$14.5 million for Q2 2026 at Nautilus Biotechnology, up from -$15.0 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$14.5 million in Q2 2026 to a low of -$15.0 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 225.48 Bn | 221.41 Bn | 8.34 Bn | 1.92 Bn |
| 2 | Danaher | 144.42 Bn | 140.08 Bn | 3.61 Bn | 1.08 Bn |
| 3 | Agilent Technologies | 40.86 Bn | 39.11 Bn | 1.04 Bn | 444.00 Mn |
| 4 | Illumina | 30.97 Bn | 29.80 Bn | 770.00 Mn | 260.00 Mn |
| 5 | Revvity | 13.85 Bn | 12.83 Bn | 416.87 Mn | 63.53 Mn |
| 6 | Bio-Techne | 11.27 Bn | 11.01 Bn | 211.39 Mn | 70.68 Mn |
| 7 | Bio-Rad Laboratories | 10.11 Bn | 8.49 Bn | 345.80 Mn | 542.10 Mn |
| 8 | Repligen | 9.33 Bn | 8.31 Bn | 110.04 Mn | 14.15 Mn |
| 9 | 10x Genomics | 8.77 Bn | 8.21 Bn | 112.50 Mn | -18.65 Mn |
| 10 | Nautilus Biotechnology | 143.03 Mn | 143.03 Mn | 175,000.00 | -14.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.46 Mn |
| Jun 30, 2025 | -15.03 Mn |
| Mar 31, 2021 | -1.78 Mn |
| Dec 31, 2020 | -576,035.00 |
| Sep 30, 2020 | -186,388.00 |